Trial reportBMC anesthesiology2026
Intraoperative remimazolam-nalbuphine infusion reduces visceral traction response during cesarean delivery: a randomised trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundVisceral traction response (VTR) occurs in over 40% of cesarean delivery under spinal anesthesia. This study evaluated the efficacy and safety of intraoperative remimazolam combined with nalbuphine for attenuating VTR.
methodsIn this prospective, randomised, double-blind, placebo-controlled trial, 72 parturients undergoing elective cesarean delivery under spinal anesthesia received either remimazolam (0.05 mg/kg) with nalbuphine (0.1 mg/kg) (R + N group, n = 36) or normal saline (Placebo group, n = 36) after umbilical cord clamping. The primary outcome was positive traction response incidence.
resultsThe R + N group demonstrated significantly lower positive traction response incidence (5.6% vs. 41.7%, p < 0.001) and reduced VTR scores during abdominal exploration and suturing. The incidence of nausea (22.2% vs 58.3%, p = 0.002) and chest tightness (8.3% vs 36.1%, p = 0.005) was significantly lower in the R + N group. Maternal satisfaction was higher (9.56 ± 0.88 vs. 7.11 ± 1.47, p < 0.001). No significant hemodynamic differences or serious adverse events occurred.
conclusionsRemimazolam combined with nalbuphine significantly reduces VTR during cesarean delivery, providing effective sedation and analgesia while maintaining hemodynamic stability, representing a safe adjunct to neuraxial anesthesia.
trial registrationChinese Clinical Trial Registry ChiCTR2500108913, registered 9 September 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.